Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arterra Bioscience (ARBS.MI)
Napoli, IT
Arterra Bioscience S.p.A. is a biotechnology company fundamentally driven by scientific research, concentrating on the discovery and development of a wide range of ingredients and nature-based solutions. The firm's activities encompass the creation of advanced technological frameworks, innovative extraction methodologies, and foundational raw materials, specifically tailored for the beauty, agricultural, and nutritional supplement sectors. Established in 2003, Arterra Bioscience S.p.A. is headquartered in Naples, Italy.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.17% | +0.71% | -8.44% | -2.76% | -5.37% | -7.84% | +23.68% | +27.03% | -30.88% | -17.30% | -17.30% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+11.4% ★ Q4'25: +91.5% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+50.0% ★ Q4'25: +16.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+5.8% Q4'25: +19.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+12.7% ★ Q4'25: +8.9% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+5.2% ★ Q4'25: +6.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.30× ★ Q4'25: 0.19× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
Dec 2027 1 Rev. Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.71M
est: 2.87M (-5.7%)
|
2.82M
est: 3.76M (-24.9%)
|
4.74M
est: 4.65M (+2.0%)
|
3.59M
est: 5.56M (-35.4%)
|
3.34M
est: 4.61M (-27.7%)
|
4.17M
est: 4.98M (-16.2%)
|
4.65M
est: 6.02M (-22.7%)
|
6.37M
6.37M – 6.37M
+5.9% YoY
|
7.12M
7.12M – 7.12M
+11.8% YoY
|
7.93M
7.93M – 7.93M
+11.4% YoY
|
| EBITDA |
1.24M
est: 1.51M (-18.3%)
|
1.60M
est: 1.98M (-19.0%)
|
1.77M
est: 2.45M (-27.8%)
|
2.34M
est: 2.93M (-20.2%)
|
1.84M
est: 2.43M (-24.1%)
|
2.04M
est: 2.62M (-22.1%)
|
881.9K
est: 3.17M (-72.2%)
|
3.35M
3.35M – 3.35M
+5.9% YoY
|
3.75M
3.75M – 3.75M
+11.8% YoY
|
4.18M
4.18M – 4.18M
+11.4% YoY
|
| EBIT |
952.4K
est: 1.15M (-17.1%)
|
1.20M
est: 1.50M (-20.0%)
|
1.28M
est: 1.86M (-31.2%)
|
1.80M
est: 2.22M (-18.8%)
|
1.31M
est: 1.84M (-28.9%)
|
1.70M
est: 1.99M (-14.5%)
|
591.8K
est: 2.41M (-75.4%)
|
2.55M
2.55M – 2.55M
+5.9% YoY
|
2.85M
2.85M – 2.85M
+11.8% YoY
|
3.17M
3.17M – 3.17M
+11.4% YoY
|
| Net Income |
857.2K
|
1.11M
|
1.11M
|
1.41M
|
1.08M
|
1.34M
|
2.01M
|
—
— – —
|
—
— – —
|
—
— – —
|
| SGA |
183.8K
est: 401.8K (-54.2%)
|
180.8K
est: 525.1K (-65.6%)
|
172.0K
est: 650.0K (-73.5%)
|
107.2K
est: 777.1K (-86.2%)
|
1.77M
est: 644.9K (+174.2%)
|
161.6K
est: 696.1K (-76.8%)
|
146.1K
est: 841.1K (-82.6%)
|
890.3K
890.3K – 890.3K
+5.9% YoY
|
995.0K
995.0K – 995.0K
+11.8% YoY
|
1.11M
1.11M – 1.11M
+11.4% YoY
|
| EPS |
0.13
|
0.17
|
0.17
|
0.21
|
0.16
|
0.20
|
0.30
|
—
— – —
|
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Giuseppe Ferrante | Chief Operating Officer & Counselor | — | male |
| Gualtiero Ioimo | Counselor, Chief Financial Officer & Investor Relations Manager | — | — |
| Maria Gabriella Colucci | Founder, Chairman of the Board, President & Chief Executive Officer | — | female |
| Vincenzo Fogliano | Chief Scientific Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARBS.MI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
